Signaling interplay between transforming growth factor-β receptor and PI3K/AKT pathways in cancer.

The transforming growth factor (TGF)-β and phosphoinositide 3-kinase/protein kinase B (PI3K/AKT) signaling pathways are used in cells to control numerous responses, including proliferation, apoptosis, and migration. TGF-β is known for its cytostatic effects in premalignant states and its pro-oncogenic activity in advanced cancers. The pro-cell survival response exerted by growth-factor-mediated activation of PI3K/AKT has been linked to stimulation of tumor formation. Both TGF-β receptor and PI3K/AKT pathways were initially modeled as linear signaling conduits. Although early studies suggested that these two pathways might counteract each other in balancing cell survival, emerging evidence has uncovered multiple modes of intricate signal integration and obligate collaboration in driving cancer progression. These new insights provide the rationale for exploring their dual targeting in cancer.

[1]  B. Kasinath,et al.  TGFβ-Stimulated MicroRNA-21 Utilizes PTEN to Orchestrate AKT/mTORC1 Signaling for Mesangial Cell Hypertrophy and Matrix Expansion , 2012, PloS one.

[2]  Robert Walgate,et al.  Proliferation , 1985, Nature.

[3]  G van der Pluijm,et al.  Smad2 and Smad3 have opposing roles in breast cancer bone metastasis by differentially affecting tumor angiogenesis , 2010, Oncogene.

[4]  William R Sellers,et al.  The biology and clinical relevance of the PTEN tumor suppressor pathway. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  C. Heldin,et al.  Regulation of EMT by TGFβ in cancer , 2012, FEBS letters.

[6]  C. Heldin,et al.  TGF-beta uses the E3-ligase TRAF6 to turn on the kinase TAK1 to kill prostate cancer cells. , 2009, Future oncology.

[7]  D. Glass.  PI3 kinase regulation of skeletal muscle hypertrophy and atrophy. , 2010, Current topics in microbiology and immunology.

[8]  C. Heldin,et al.  The type I TGF-β receptor engages TRAF6 to activate TAK1 in a receptor kinase-independent manner , 2008, Nature Cell Biology.

[9]  P. ten Dijke,et al.  The tumor suppressor Smad4 is required for transforming growth factor beta-induced epithelial to mesenchymal transition and bone metastasis of breast cancer cells. , 2006, Cancer research.

[10]  Akhurst,et al.  Title Targeting the TGFβ signalling pathway in disease , 2012 .

[11]  Rulong Z. Shen,et al.  Dichotomy effects of Akt signaling in breast cancer , 2012, Molecular Cancer.

[12]  J. Massagué.  TGFβ signalling in context , 2012, Nature Reviews Molecular Cell Biology.

[13]  Xi He,et al.  Control of β-Catenin Phosphorylation/Degradation by a Dual-Kinase Mechanism , 2002, Cell.

[14]  Roger R. Gomis,et al.  TGFβ Primes Breast Tumors for Lung Metastasis Seeding through Angiopoietin-like 4 , 2008, Cell.

[15]  C. Rüegg,et al.  Akt/PKB-mediated phosphorylation of Twist1 promotes tumor metastasis via mediating cross-talk between PI3K/Akt and TGF-β signaling axes. , 2012, Cancer Discovery.

[16]  Christopher S. Chen,et al.  Matrix rigidity regulates a switch between TGF-β1–induced apoptosis and epithelial–mesenchymal transition , 2012, Molecular biology of the cell.

[17]  B. Snaar-Jagalska,et al.  Snail and Slug, key regulators of TGF-β-induced EMT, are sufficient for the induction of single-cell invasion. , 2013, Biochemical and biophysical research communications.

[18]  M. Roizen,et al.  Hallmarks of Cancer: The Next Generation , 2012 .

[19]  Wolfgang Link,et al.  The PTEN/PI3K/AKT signalling pathway in cancer, therapeutic implications. , 2008, Current cancer drug targets.

[20]  Xin Lin,et al.  The E3 Ligase TRAF6 Regulates Akt Ubiquitination and Activation , 2009, Science.

[21]  Kohei Miyazono,et al.  Transforming growth factor-beta signaling in epithelial-mesenchymal transition and progression of cancer. , 2009, Proceedings of the Japan Academy. Series B, Physical and biological sciences.

[22]  C. Cordon-Cardo,et al.  A multigenic program mediating breast cancer metastasis to bone. , 2003, Cancer cell.

[23]  G. Tzivion,et al.  FoxO transcription factors; Regulation by AKT and 14-3-3 proteins. , 2011, Biochimica et biophysica acta.

[24]  D. Richardson,et al.  The TGF-beta, PI3K/Akt and PTEN pathways: established and proposed biochemical integration in prostate cancer. , 2009, The Biochemical journal.

[25]  Samy Lamouille,et al.  Cell size and invasion in TGF-β–induced epithelial to mesenchymal transition is regulated by activation of the mTOR pathway , 2007, The Journal of cell biology.

[26]  Stephen W. Michnick,et al.  PKB/Akt modulates TGF-β signalling through a direct interaction with Smad3 , 2004, Nature Cell Biology.

[27]  Samy Lamouille,et al.  TGF-β-induced epithelial to mesenchymal transition , 2009, Cell Research.

[28]  안성민.  Development of Personalized Tumor Biomarkers Using Massively Parallel Sequencing , 2011 .

[29]  K. Luo,et al.  Akt interacts directly with Smad3 to regulate the sensitivity to TGF-β-induced apoptosis , 2004, Nature Cell Biology.

[30]  J. Rossi,et al.  TGF-β activates Akt kinase via a microRNA-dependent amplifying circuit targeting PTEN , 2009, Nature Cell Biology.

[31]  L. Cantley,et al.  Apoptosis: A Bad kinase makes good , 1997, Nature.

[32]  C. Creighton,et al.  COUP-TFII inhibits TGF-β-induced growth barrier to promote prostate tumorigenesis , 2012, Nature.

[33]  Pixu Liu,et al.  Targeting the phosphoinositide 3-kinase pathway in cancer , 2009, Nature Reviews Drug Discovery.

[34]  R. Bernards,et al.  MED12 Controls the Response to Multiple Cancer Drugs through Regulation of TGF-β Receptor Signaling , 2012, Cell.

[35]  M. Roussel,et al.  Glycogen synthase kinase-3beta regulates cyclin D1 proteolysis and subcellular localization. , 1998, Genes & development.

[36]  G. Kleemann,et al.  TGF-β and Insulin Signaling Regulate Reproductive Aging via Oocyte and Germline Quality Maintenance , 2010, Cell.

[37]  B. Hemmings,et al.  PKB/Akt-dependent regulation of cell motility. , 2013, Journal of the National Cancer Institute.

[38]  M. Landström,et al.  Non-Smad signaling pathways , 2011, Cell and Tissue Research.

[39]  D. Sabatini,et al.  Regulation of the mTOR complex 1 pathway by nutrients, growth factors, and stress. , 2010, Molecular cell.

[40]  C. Heldin,et al.  Non-Smad TGF-β signals , 2005, Journal of Cell Science.

[41]  J. Massagué,et al.  TGFβ in Cancer , 2008, Cell.

[42]  Jeff Porter,et al.  USP4 is regulated by AKT phosphorylation and directly deubiquitylates TGF-β type I receptor , 2012, Nature Cell Biology.

[43]  A. Brunet,et al.  FOXO transcription factors , 2007, Current Biology.

[44]  Carlos L. Arteaga,et al.  Transforming Growth Factor (cid:2) Engages TACE and ErbB3 To Activate Phosphatidylinositol-3 Kinase/Akt in ErbB2-Overexpressing Breast Cancer and Desensitizes Cells to Trastuzumab (cid:1) † , 2008 .

[45]  C. Chung,et al.  Inhibition of TGF-β Enhances the In Vivo Antitumor Efficacy of EGF Receptor–Targeted Therapy , 2012, Molecular Cancer Therapeutics.

[46]  J. Massagué,et al.  TGFbeta signaling in growth control, cancer, and heritable disorders. , 2000, Cell.

[47]  Massimo Cristofanilli,et al.  Circulating Breast Tumor Cells Exhibit Dynamic Changes in Epithelial and Mesenchymal Composition , 2013 .

[48]  J. Cheng.  Editorial [Hot Topic: Akt Pathway in Oncogenesis and as a Target for Anti-Cancer Therapy (Guest Editor: Jin Q. Cheng) ] , 2008 .

[49]  V. Speirs,et al.  The practicalities of using tissue slices as preclinical organotypic breast cancer models , 2012, Journal of Clinical Pathology.

[50]  Suimin Qiu,et al.  Stabilization of snail by NF-kappaB is required for inflammation-induced cell migration and invasion. , 2009, Cancer cell.

[51]  H. Moses,et al.  Phosphatidylinositol 3-Kinase Function Is Required for Transforming Growth Factor β-mediated Epithelial to Mesenchymal Transition and Cell Migration* , 2000, The Journal of Biological Chemistry.

[52]  M. Yamashita,et al.  TRAF6 mediates Smad-independent activation of JNK and p38 by TGF-beta. , 2008, Molecular cell.

[53]  Sophie J Deharvengt,et al.  Concomitant Targeting of EGF Receptor, TGF-beta and Src Points to a Novel Therapeutic Approach in Pancreatic Cancer , 2012, PloS one.

[54]  P. Dijke,et al.  The FYVE domain in Smad anchor for receptor activation (SARA) is sufficient for localization of SARA in early endosomes and regulates TGF‐β/Smad signalling , 2002, Genes to cells : devoted to molecular & cellular mechanisms.

[55]  W. Kong,et al.  Advances of AKT pathway in human oncogenesis and as a target for anti-cancer drug discovery. , 2008, Current cancer drug targets.

[56]  Ying E Zhang,et al.  Non-Smad pathways in TGF-β signaling , 2009, Cell Research.

[57]  P. Cohen,et al.  Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B , 1995, Nature.

[58]  P. Bourne,et al.  CYLD negatively regulates transforming growth factor-β-signalling via deubiquitinating Akt , 2012, Nature Communications.

[59]  J. Massagué,et al.  Cytostatic and apoptotic actions of TGF-β in homeostasis and cancer , 2003, Nature Reviews Cancer.

[60]  H. Beug,et al.  Molecular requirements for epithelial-mesenchymal transition during tumor progression. , 2005, Current opinion in cell biology.

[61]  Gerald C. Chu,et al.  SMAD4-dependent barrier constrains prostate cancer growth and metastatic progression , 2011, Nature.

[62]  L. Nelles,et al.  Activation of NF-κB by Akt upregulates Snail expression and induces epithelium mesenchyme transition , 2007, Oncogene.

[63]  C. Heldin,et al.  Signaling networks guiding epithelial–mesenchymal transitions during embryogenesis and cancer progression , 2007, Cancer science.

[64]  K. Hui,et al.  MicroRNA‐216a/217‐induced epithelial‐mesenchymal transition targets PTEN and SMAD7 to promote drug resistance and recurrence of liver cancer , 2013, Hepatology.

[65]  Samy Lamouille,et al.  TGF-&bgr; signaling and epithelial–mesenchymal transition in cancer progression , 2013, Current opinion in oncology.

[66]  Wei He,et al.  Breast cancer bone metastasis mediated by the Smad tumor suppressor pathway. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[67]  L. Cantley,et al.  New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase/AKT pathway. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[68]  A. Pozzi,et al.  Transforming growth factor beta induces clustering of HER2 and integrins by activating Src-focal adhesion kinase and receptor association to the cytoskeleton. , 2009, Cancer research.

[69]  Hong-Jian Zhu,et al.  Proteome profiling of exosomes derived from human primary and metastatic colorectal cancer cells reveal differential expression of key metastatic factors and signal transduction components , 2013, Proteomics.

[70]  H. van Dam,et al.  Key signaling nodes in mammary gland development and cancer: Smad signal integration in epithelial cell plasticity , 2012, Breast Cancer Research.

[71]  M. Hung,et al.  Dual regulation of Snail by GSK-3β-mediated phosphorylation in control of epithelial–mesenchymal transition , 2004, Nature Cell Biology.

[72]  David M Reynolds,et al.  Signaling network crosstalk in human pluripotent cells: a Smad2/3-regulated switch that controls the balance between self-renewal and differentiation. , 2012, Cell stem cell.

[73]  Hans Clevers,et al.  Long-term expansion of epithelial organoids from human colon, adenoma, adenocarcinoma, and Barrett's epithelium. , 2011, Gastroenterology.

[74]  G. Krystal,et al.  Activin/TGF-β induce apoptosis through Smad-dependent expression of the lipid phosphatase SHIP , 2002, Nature Cell Biology.

[75]  S. Anderson,et al.  Integration of Smad and Forkhead Pathways in the Control of Neuroepithelial and Glioblastoma Cell Proliferation , 2004, Cell.

[76]  M. Nieto,et al.  The Snail genes as inducers of cell movement and survival: implications in development and cancer , 2005, Development.

[77]  Jae Youn Yi,et al.  Type I Transforming Growth Factor β Receptor Binds to and Activates Phosphatidylinositol 3-Kinase* , 2005, Journal of Biological Chemistry.